36 results about "Rheumatoide arthritis" patented technology

The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis.

The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition selected from the group consisting of pains, including the phase 1 pain and the phase 2 pain, anxiety and stress. The composition is particularly beneficial to alleviating or getting rid of the pain and anxiety which significantly lower quality of life of patients with end-stage cancer. The composition of this invention is also useful for treatment of pains, including the phase 1 pain and the phase 2 pain, and inflammation which accompany arthritis or diseases in the junctions of bones (e.g. rheumatoid arthritis, osteoarthritis, frozen shoulder, sports injuries such as tennis elbow and baseball shoulder, and low back pain).

A Chinese medicine in the form of decoction for treating strong pain type rheumatoid arthritis is prepared from 21 Chinese-medicinal materials including Chinese angelica root, prepared rehmannia root, white peony root, pilose asiabell root, etc. Its preparing process is also disclosed.

The invention discloses a traditional herbal preparation for treating rheumatoid arthritis. The traditional herbal preparation is an internal Chinese medicine extract. The traditional herbal preparation is prepared from, by mass, 35 parts of radix astragali, 15 parts of ramulus cinnamomi, 25 parts of parched white peony root, 10 parts of radix aconiti lateralis preparata, 15 parts of radix angelicae sinensis, 25 parts of semen coicis, 15 parts of radix sileris, 15 parts of radix gentianae macrophyllae, 10 parts of rhizoma et radix notopterygii, 10 parts of rhizome chuanxiong, 15 parts of rhizoma atractylodis and 15 parts of licorice root. The traditional herbal preparation has small side effects when used for treating rheumatoid arthritis. By detecting the articular swelling degree and thecontent of RF, TNF alpha, IL-6 and IL-10 in serum of a mouse after treatment, the result shows that the traditional herbal preparation has a better curative effect on rheumatoid arthritis than a preparation in the prior art does.

The externally applied liniment for treating rheumatoid arthritis consists of active components and carrier. The active components consists of frankincense 23.6-33.6 wt%, papaya 9.2-19.2 wt%, buck grass 9.2-19.2 wt%, camphor 37.7-47.7 wt% and musk 0.25-0.35 wt%; and the carrier is 70-75 % concentration alcohol solution. The preparation process includes decocting frankincense, papaya and grass, filtering to eliminate dregs, concentrating, adding ground musk and camphor and 70-75 % concentration alcohol solution, and mixing. The externally applied liniment is applied to the affected part to treat rheumatoid arthritis, joint strain sequela and other diseases.

The invention discloses a blood marker-PGK1 for rheumatoid arthritis clinical diagnosis, and discloses a reagent for rheumatoid arthritis clinical diagnosis. The reagent comprises a PGK1 antibody, an HRP-IgG antibody and a conventional reagent in a blood diagnosis reagent. The conventional reagent in the blood diagnosis reagent comprises a carbonate buffer solution, PBST washing liquor, confining liquid, a developing solution and a stop solution. The prepared detection reagent has the advantages of being high in sensitivity, high in specificity and the like and is capable of being widely applied to preliminary survey and health examination of clinical rheumatoid arthritis and providing a reliable basis for clinical diagnosis.

The invention relates to a pharmaceutical composition for treating rheumatoid arthritis. The invention is developed based on traditional Chinese medicine basic theory, and comprises traditional Chinese medicine raw material herbs of radix angelicae pubescentis, notopterygium roots, radices sileris, angelica, white peony roots, radix aconiti preparata, prepared kusnezoff monkshood roots, parasitic loranthus, eucommia, rhizoma dioscoreae nipponicae, peach kernels, safflower, ligusticum wallichii, radix angelicae, licorice, etc. The pharmaceutical composition of the invention has the efficacy of nourishing blood, relaxing muscles and tendons, dispelling wind, eliminating dampness, removing rheumatism, and relieving pain, and is used for treating rheumatoid arthritis clinically.

The name of the invention is application of an anti-CiP antibody in diagnosis of an early rheumatoid arthritis. The invention provides a method for CiP and analogues thereof for detection of the early rheumatoid arthritis (RA). A polypeptide antigen can be specifically combined with a specific antibody inside a body of a sufferer with the early RA, the anti-CiP antibody has high sensitivity and specificity, and has high positive rate in the sufferer with the early RA having negative IgM-RF or anti-CCP antibody, and detection results of an anti-keratin antibody (AKA) and an antiperinuclear factor (APF). Auxiliary diagnosis of the sufferer with the negative IgM-RF antibody or the negative anti-CCP antibody is facilitated.

The invention discloses a traditional Chinese medicine for curing rheumatoid arthritis, wherein the traditional Chinese medicine is prepared from 17 crude drugs of astragalus membranaceus, pawpaw, codonopsis pilosula, notopterygium root, rhizoma corydalis, cassia twig, myrrh, rhizoma atractylodis, ligusticum wallichii, radix angelicae pubescentis, cortex phellodendri chinensis, radix clematidis, parasitic loranthus, caulis spatholobi, angelica sinensis, dried tangerine or orange peel and schisandra chinensis. The traditional Chinese medicine for curing the rheumatoid arthritis has the advantages that the medicinal properties of all drugs supplement each other, so that not only is the effect of obviously curing the rheumatoid arthritis achieved, but also the torture to patients from the rheumatoid arthritis can be greatly relieved, root causes and symptoms of the rheumatoid arthritis are both cured, and the patients cannot be subjected to side effects and bad influences.

The invention confirms the suppression effect of paclitaxel liposome on B cell proliferation and immunologic function, and the application of paclitaxel liposome on rat CIA treatment.

The invention relates to a drug for treating rheumatoid arthritis. The drug for treating the rheumatoid arthritis is prepared from, by weight, 2 parts of Chinese pyrola herbs, 3 parts of radix paeoniae alba, 3 parts of phlomis medicinalis diels, 4 parts of herba lycopodii, 3 parts of ramulus mori, 5 parts of rhizoma et radix notopterygii, 3 parts of radix saposhnikoviae and 6 parts of Chinese wolfberry fruit. According to the drug for treating the rheumatoid arthritis, Chinese pyrola herbs have the functions of clearing damp and strengthening tendons; radix paeoniae alba has the functions of calming the liver, relieving pains and nourishing blood for regulating menstruation; phlomis medicinalis diels has the functions of expelling wind-damp and expelling wind-damp; herba lycopodii has the functions of dispelling wind, eliminating dampness, relaxing tendons and activating collaterals; ramulus mori has the functions of expelling the wind-damp and facilitating joints; rhizoma et radix notopterygii has the functions of dispelling cold and wind-evil, removing damp and stopping the pains; radix saposhnikoviae has the functions of relieving exterior syndrome and dispelling the wind-evil; Chinese wolfberry fruit has the function of nourishing the liver and the kidney. All the medicines are combined for use, the efficacy of tonifying the kidney, dredging collaterals, dispelling the wind and eliminating the damp is achieved through all the medicines, and the rheumatoid arthritis is effectively treated. According to clinical experiments, it is verified that the drug can safely and effectively treat the rheumatoid arthritis.

The invention aims at providing a method for preparing functional soft capsules for treating rheumatoid diseases. The soft capsules for treating rheumatoid diseases have the advantages that patients can orally take conveniently, the effect is good and the cost is low. The invention provides a pharmaceutical preparation for treating rheumatoid arthritis, wherein the pharmaceutical preparation is prepared from medicaments, such as himalayan teasel root, centipedes, safflower, scorpion, radix cyathulae, licorice root, camphor, long-nosed pit viper, medlar, eucommia bark and the like. The pharmaceutical preparation provided by the invention per dose contains 200g of himalayan teasel root, 200g of safflower, 200g of radix cyathulae, 200g of licorice root, 200g of camphor, 200g of medlar, 200g of scorpion, 200g of eucommia bark, ten centipedes and two long-nosed pit vipers. The pharmaceutical preparation provided by the invention is prepared through preparing a high-concentration medicated liquid preparation from Chinese herbal medicine ingredients and then filling the high-concentration medicated liquid preparation into soft capsules or wax pills.

The invention belongs to the field of medicinal application invention, particularly discloses application of a linalool compound in preparation of a medicine for treating rheumatoid arthritis, and discloses the possibility of linalool serving as a natural medicinal material extract for achieving the remarkable effects of multi-target, low toxicity and high efficiency on rheumatoid arthritis, improving the cure rate for patients with rheumatoid arthritis and reducing administration varieties and dosage through a multi-action mechanism of relieving paw edema of an AA rat, reducing 50 percent ofpain threshold ED50 of the AA rat, relieving ankle joint pathologic change and immune organ pathologic change of the AA rat, inhibiting the proinfammatory cytokines expression level of IL-1beta, IL-6and IL-10 in serum of the AA rat and / or inhibiting expression of NF-kappa B / p65 protein in the ankle joint of the AA rat. The linalool compound has a remarkable progressive meaning when being appliedto preparation of medicine for treating rheumatoid arthritis.

The invention relates to the use of apple polyphenol in preparing medicaments or health products for the treatment and / or prevention of rheumathritis or rheumatoid arthritis pertaining to the field of pharmaceuticals or health products, wherein apple polyphenol obtained through industrialized production is used as the raw material. The pharmaceuticals and health products can be obtained through conventional preparing processes for for mass production at low cost.

The invention discloses a drug for treatment of rheumatoid arthritis. The drug comprises by weight: the following medicinal components: 300 parts of Radix Aconiti Kusnezoffii Praeparata, 180 parts of piper longum, and 600 parts of Terminalia chebula Retz; the following gel matrix: 12 parts of carbomer 940, 14 parts of triethanolamine, 90 parts of propylene glycol, and 45 parts of Twain-80; the following transdermal penetration enhancers: 45 parts of azone, and 1.5 parts of sorbic acid; a moderate amount of distilled water, with a total of 1000 parts. And the materials are made into a gel, which has the characteristics of quick and good curative effect.

The invention discloses separation and preparation of a euphorbia factor L2 and a novel application of the euphorbia factor L2 to treatment of rheumatoid arthritis, and belongs to the field of traditional Chinese medicines. The euphorbia factor L2 is a diterpene ester compound extracted from semen euphorbiae lathyridis serving as a traditional Chinese medicinal material and displays good treatmenteffects on a serum metastasis induced inflammatory arthritis mouse model, and the euphorbia factor L2 has exact functions of resisting osteoarticular inflammatory diseases such as the rheumatoid arthritis and can be combined with auxiliary materials to prepare a medicine for resisting the inflammatory diseases such as the rheumatoid arthritis or combined with other medicines for treating the rheumatoid arthritis in application.

Linderolide H for treating immune inflammations is used to prepare drugs for treating rheumatoid arthritis; by using terfenadine and diclofenac as controls, Linderolide H has exact treatment effect; the application of Linderolide H related herein in the preparation of drugs for treating rheumatoid arthritis is disclosed for the first time; since a framework is of brand-new type and the inhibitory activity for rheumatoid arthritis is unexpectedly high, there is no chance for other compounds to give any indication and outstanding practical characteristics are provided; in addition, Linderolide H has significant progress in preventing and treating rheumatoid arthritis.

The invention relates to Nardoaristolones A for treating immune inflammation and the Nardoaristolones can be used for preparing medicines for treating rheumatoid arthritis. Terfenadine and diclofenac sodium are taken as control, and the curative effect of Nardoaristolones A is exact. The use of Nardoaristolones A for preparing medicines for treating rheumatoid arthritis provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, Nardoaristolones A has remarkable substantive characteristics and obviously has remarkable progress for preventing and treating rheumatoid arthritis.

According to the invention, 26 types of proteins have differential expression in immune complexes of serums of an RA (rheumatoid arthritis) patient and a normal collator through the mass spectrometry, wherein LBP (lipopolysaccharide binding protein) is proved to be increased in RA circulating immune complexes; according to a further research, LBP is a specificity serum marker of RA and has an important role in assessing and diagnosing activity of RA. The invention aims to apply the enzyme linked immunosorbent assay to detect the LBP level, diagnose RA and assess the disease activity.

The invention relates to the technical field of sports apparatus, which discloses a rheumatoid arthritis sports healing machine. In order to solve the problem that the prior sports apparatus is not suitable for rheumatoid arthritis patients, the rheumatoid arthritis sports healing machine adopts the technical proposal that the healing machine comprises a sports device arranged on a base (5), a fixed foot pedal vehicle, a supporting frame and a simple vehicle wheel (4). The rheumatoid arthritis sports healing machine is characterized in that the supporting frame comprises a front supporting frame (6), a back supporting frame (10) and a mechanism (9) for regulating pressure (9); the upper end of the front supporting frame (6) is connected with a vehicle body (7), while the lower end is connected with the base (5); the back supporting frame (10) comprises a mounting frame and a rotating roller, the mounting frame is connected with the base (5) fixedly, the rotating roller is connected with the mounting frame rotatablely, and the rotating roller is positioned at the bottom of the vehicle wheel (4); and the mechanism(9) for regulating the pressure is arranged between the vehicle body (7) and the base (5). The rheumatoid arthritis sports healing machine has the advantages of having a plurality of sports apparatus, carrying out the slightest sports, and the like.

The invention relates to a traditional Chinese medicinal composition for treating rheumatoid arthritis. The traditional Chinese medicinal composition is prepared from the following crude drugs in parts by weight: 50-210 parts of tripterygium wilfordii, 5-50 parts of radix rehmanniae recen, 10-90 parts of rhizoma atractylodis, 10-90 parts of caulis lonicerae, 10-90 parts of tribulus terrestris, 25-120 parts of radix codonopsis and 10-30 parts of fruit of Chinese wolfberry, wherein the ratio of tripterygium wilfordii to fruit of Chinese wolfberry is 5-7 to 1. Clinical research proves that the total effective rate of the traditional Chinese medicinal composition on rheumatoid arthritis can reach 95.6%, can effectively relieve related symptoms, and is safe and effective.

The invention provides a pharmaceutic preparation for treating rheumatoid arthritis and application thereof. The pharmaceutic preparation is prepared from, by weight, 6-15 parts of common threewingnut roots, 3-12 parts of suberect spatholobus stems, 20-30 parts of radix paeoniae alba, 15-20 parts of stems of caulis sinomenii, 10-20 parts of radix angelicae pubescentis, 20-30 parts of Japanese knotweed, 10-20 parts of arteannuin, 10-15 parts of raw liquorice roots, 20-30 parts of milkvetch roots, 10-20 parts of radix angelica sinensis, 9-15 parts of radix rehmanniae recen, 3-9 parts of stiff silkworms, 6-12 parts of earthworms, 10-20 parts of semen brassicae, 5-15 parts of rhizoma pinelliae and 10-20 parts of rhizoma curcumae. The adopted traditional Chinese medicine composition is clinically applied for many years, composition differentiation is reasonable, scientific and precise, the composition is mainly added and reduced according to the etiology and pathogenesis of wind, cold and dampness of rheumatoid arthritis, common threewingnut roots have the functions of dispelling wind and eliminating dampness, relaxing tendon and activation collaterals, diminishing inflammation and relieving pain and the like, and the aim of treating rheumatoid arthritis is achieved together. A good treatment effect is achieved. Use is convenient, no toxic or side effect exists, and application and popularization are convenient.

The invention provides an application of trillium tschonoskii total saponins in preparation of a medicine for treating rheumatoid arthritis. The effect of the trillium tschonoskii total saponins on adjuvant-induced arthritis model rat inflammation is researched from an NOD-like receptor protein 3 / cysteine aspartic protease 1 pathway. The SD rats are randomly divided into a blank group, a model group, a tripterygium glycosides group, a trillium tschonoskii total saponin low-dose group, a trillium tschonoskii total saponin medium-dose group and a trillium tschonoskii total saponin high-dose group, and each group comprises six rats. The result shows that compared with the Control group, the foot swelling degree, the arthritis score, the serum TNF-alpha, IL-1beta and IL-6 levels of the AA group, the NLRP3 protein expression level in synovial tissues and the NLRP3, ASC and Caspase-1 protein levels in ankle joints are all remarkably improved; knee joint synovial cell proliferation, interstitial edema and inflammatory cell infiltration of the AA group rats; and after treatment with TG and TTM with different doses, the indexes are all improved to different degrees.

The invention discloses a compound traditional Chinese medicine for treating acute-phase rheumatoid arthritis. The compound traditional Chinese medicine comprises raw materials of milkvetch root, roasted thinleaf milkwort root-bark, stem of noble dendrobium, achyranthes root, Japanese honeysuckle stem, Szechuan lovage rhizome, processed common monkshood root, Chinese waxgourd peel, glabrous greenbrier rhizome, and rhizoma corydalis; the milkvetch root in the formula is used as a sovereign drug, which is an effective medicine for invigorating qi, and is used for maintaining vital qi to lead other medicines to illness stations, thereby removing obstruction and stagnation and driving away pathological factors. The achyranthes root is capable of nourishing Yin and strengthening Yang, strengthening tendons and bones, and removing blood stasis to stop blood stasis, and is good at treating inhibited bending and stretching of joints; the stem of noble dendrobium is capable of nourishing Yin to produce body fluid; the thinleaf milkwort root-bark is capable of invigorating heart and kidney; the medicines are used as ministerial drugs which can eliminate an inward spreading path of pathogenic factors, and strengthen unaffected parts, and can remove phlegm and eliminate pains and swelling. The processed common monkshood root is capable of dispersing cold and relieving pain; the Szechuan lovage rhizome and the rhizoma corydalis are capable of promoting blood and Qi circulation to relieve pains to achieve an effect of removing stasis and pains automatically by promoting blood and Qi circulation; the Chinese waxgourd peel and the glabrous greenbrier rhizome are capable of eliminating dampness to relieve pains, easing joint movement and eliminating swelling; the Japanese honeysuckle stem is capable of clearing away heat and toxic materials, can eliminate painful swelling of joints caused by heat generated by stases, and can restrict the warm nature of the milkvetch root, and these medicines are used as adjuvant drugs. All the raw medicinal materials work together to achieve the effects of promoting circulation of blood to remove arthralgia, relieving swelling and pains while taking care of the stomach. All kinds of medicines are combined to achieve the functions of strengthening healthy energy to eliminate swelling, and dispelling cold and relieving pains.

The invention provides Gypensapogenin A for treating immune inflammation and application of Gypensapogenin A in a medicine for treating rheumatoid arthritis. Compared with terfenadine and diclofenac sodium, Gypensapogenin A has accurate curative effects. The application of Gypensapogenin B in preparing the medicine for treating rheumatoid arthritis, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the rheumatoid arthritis inhibiting activity of Gypensapogenin A is extremely strong, so that no possibility for providing any prompt by other compounds exists. Gypensapogenin A has outstanding actual characteristics. Meanwhile, Gypensapogenin A has outstanding progress when being used for preventing and treating rheumatoid arthritis.

The invention relates to Nardoaristolones A for treating immune inflammation and the Nardoaristolones can be used for preparing medicines for treating rheumatoid arthritis. Terfenadine and diclofenac sodium are taken as control, and the curative effect of Nardoaristolones A is exact. The use of Nardoaristolones A for preparing medicines for treating rheumatoid arthritis provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, Nardoaristolones A has remarkable substantive characteristics and obviously has remarkable progress for preventing and treating rheumatoid arthritis.

An Apigenin for treating immune inflammation is used to prepare a medicine for treating rheumatoid arthritis. Terfenadine and diclofenac are used as controls, and the curative effect of Apigenin is clear. The use of Apigenin involved in the present invention in the preparation of drugs for the treatment of rheumatoid arthritis is disclosed for the first time. Since the skeleton type belongs to a brand-new skeleton type, and its inhibitory activity against rheumatoid arthritis is so strong that it is unexpected, there is no evidence given by other compounds. The possibility of enlightenment has outstanding substantive features, and at the same time it is obviously a significant progress in the prevention and treatment of rheumatoid arthritis.

The invention provides the application of berberine in the preparation of medicines for preventing and treating rheumatoid arthritis. The invention adopts the berberine to carry out the animal efficacy test, and the result shows that the berberine can inhibit the clinical onset of collagen-induced arthritis, and obviously inhibit the severity and incidence rate of the onset. And can down-regulate tumor necrosis factor α, interleukin 17, interferon γ in spleen cell supernatant, inhibit the secretion of pro-inflammatory cytokines TNF-α, IFN-γ and IL-17, so as to prepare drugs for preventing and treating rheumatoid arthritis, It has great clinical application value. The medicine is a pharmaceutical composition made of berberine as an active ingredient and conventional pharmaceutical excipients, including tablets, dispersible tablets, buccal tablets, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, Granules, injections, powder injections or aerosols.